Bioinova (Czechia)

A roadmap for clinical-grade manufacturing of hiPSC: standardized methodologies for reprogramming, expansion, characterization, and biobanking of hiPSC

There is a critical global need for tissue for transplantation in patients with organ failure or degenerative diseases, which often have limited or no treatment options. Cell therapy using human induced pluripotent stem cells (hiPSC) represents a promising alternative to restore...